Lataa...
Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony
PURPOSE OF REVIEW: Fibroblast growth factor 23 (FGF23) is a key phosphate-regulating hormone that has been associated with adverse outcomes in patients with chronic kidney disease (CKD). Emerging data suggest that FGF23 plays a specific role in type 2 diabetes, partly independent of kidney function....
Tallennettuna:
| Julkaisussa: | Curr Diab Rep |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer US
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7455586/ https://ncbi.nlm.nih.gov/pubmed/32857288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11892-020-01335-7 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|